Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 8/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.48 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18041596 | 1.00 | FGFR1 (0.49) | FGFR1TGFBR1TGFBR2FGFR2FGFR3 | |
| SCHEMBL18041541 | 0.92 | TGFBR1 (0.50) | TGFBR1TGFBR2MAPK14 | |
| SCHEMBL29677032 | 0.92 | TGFBR1 (0.50) | TGFBR1TGFBR2MAPK14 | |
| SCHEMBL18041819 | 0.83 | TGFBR1 (0.70) | FGFR1TGFBR1TGFBR2FGFR2FGFR3 | |
| SCHEMBL29677020 | 0.83 | TGFBR1 (0.70) | FGFR1TGFBR1TGFBR2FGFR2FGFR3 | |
| SCHEMBL8264120 | 0.83 | FGFR1 (0.70) | FGFR1TGFBR1TGFBR2FGFR2FGFR3 | |
| SCHEMBL18042030 | 0.82 | TGFBR1 (0.61) | FGFR1TGFBR1TGFBR2FGFR2FGFR3 | |
| SCHEMBL29677143 | 0.82 | TGFBR1 (0.61) | FGFR1TGFBR1TGFBR2FGFR2FGFR3 | |
| SCHEMBL17767591 | 0.79 | TGFBR1 (0.43) | FGFR1TGFBR1TGFBR2FGFR2FGFR3 | |
| SCHEMBL17767790 | 0.79 | TGFBR1 (0.43) | FGFR1TGFBR1TGFBR2FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352360-B2 | TGF-beta inhibitors | Rigel Pharmaceuticals, hic. (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352360-B2 | TGF-beta inhibitors | TGFBR1, TGFBR2, TGFB1 | FGFR1 120/4885TGFBR1 1/4885TGFBR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.